ICICI Securities Sets Rs 290 Target for Piramal Pharma
The brokerage said Piramal Pharma's Q2FY27 EBITDA was 39% ahead of its estimate and CDMO growth was 36.4% year over year.
Related stories
European session market picture: S&P 500 -0.9%, Nasdaq 100 -2.02%; EUR/USD +0.11%, WTI +1.47%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 0.9 percent, Nasdaq futures is down 2.02 percent, Dow futures is up 0.02 percent and Russell futures is d
M impact | EQUITY | Oct 30, 2026, 07:30 AM UTC
S&P 500 E-mini Futures Fall 0.9%, Nasdaq 100 Futures Drop 2%
Dow futures were flat.
M impact | EQUITY | Oct 30, 2026, 07:29 AM UTC
Deutsche Bank raises Aixtron to Buy from Hold
Deutsche Bank raised its rating on Aixtron to Buy from Hold.
M impact | EQUITY | Oct 30, 2026, 07:29 AM UTC
Amazon Shares Fall 7.21% After Hours
Amazon shares fell 7.21% in after-hours trading.
M impact | EQUITY | Oct 30, 2026, 07:25 AM UTC
Ueda Says Trading Volume Fell Short of Assumption in BOJ ETF Sales Decision
BOJ Governor Kazuo Ueda said market trading volume increased, while actual volume was below the level initially assumed in the decision to accelerate ETF sales.
M impact | EQUITY | Oct 30, 2026, 07:24 AM UTC
Sylvania Platinum Q1 Revenue Rises 30% on Record PGM Output
Sylvania Platinum reported a 30% rise in Q1 revenue alongside record PGM output.
M impact | EQUITY | Oct 30, 2026, 07:24 AM UTC